1. *HCN4* and Familial Sick Sinus Syndrome
==========================================

The "sick sinus syndrome" has been defined as the "intrinsic inadequacy of the sinoatrial node (SAN) to perform its pacemaking function due to a disorder of automaticity and/or inability to transmit its impulse to the rest of the atrium" \[[@B1-ijms-16-03071]\]. In 2003, Schulze-Bahr *et al.* \[[@B2-ijms-16-03071]\] were the first to link familial sick sinus syndrome to mutations in the hyperpolarization-activated cyclic nucleotide-gated (HCN) gene family that mediates the hyperpolarization-activated "pacemaker current" or "funny current" (*I*~f~) in the heart (for reviews, see \[[@B3-ijms-16-03071],[@B4-ijms-16-03071],[@B5-ijms-16-03071],[@B6-ijms-16-03071],[@B7-ijms-16-03071]\]). The HCN channel family comprises four members, HCN1--HCN4, which can form HCN channels in homomeric, as well as heteromeric tetramers. The four HCN family members display distinct expression patterns in the body (for reviews, see \[[@B4-ijms-16-03071],[@B8-ijms-16-03071],[@B9-ijms-16-03071],[@B10-ijms-16-03071]\]), but the dominant HCN transcript in the human SAN is HCN4 \[[@B11-ijms-16-03071]\]. It is, therefore, not surprising that the *HCN4* locus has been identified as a modulator of heart rate in a genome-wide association study (GWAS) \[[@B12-ijms-16-03071]\] and that reduced *HCN4* expression due to endurance exercise is associated with a lower resting heart rate \[[@B13-ijms-16-03071]\]. A reduced *HCN4* expression is also associated with a lower heart rate in animal models of heart failure \[[@B14-ijms-16-03071]\] and aging \[[@B15-ijms-16-03071]\]. Less obviously, the *HCN4* locus had already been identified as a susceptibility locus for atrial fibrillation (AF) in another GWAS \[[@B16-ijms-16-03071]\].

Both HCN1-deficient \[[@B17-ijms-16-03071]\] and HCN2-deficient \[[@B18-ijms-16-03071]\] transgenic mice may display a sick sinus syndrome phenotype. However, till now, reports of mutations affecting *I*~f~ in the human heart have been restricted to the *HCN4* gene \[[@B2-ijms-16-03071],[@B19-ijms-16-03071],[@B20-ijms-16-03071],[@B21-ijms-16-03071],[@B22-ijms-16-03071],[@B23-ijms-16-03071],[@B24-ijms-16-03071],[@B25-ijms-16-03071],[@B26-ijms-16-03071],[@B27-ijms-16-03071],[@B28-ijms-16-03071]\] or the *KCNE2* gene \[[@B29-ijms-16-03071]\], which encodes the MiRP1 modulatory subunit of the *I*~f~ channel. Voltage-clamp experiments on wild-type and mutant human HCN4 channels expressed in COS-7, CHO and HEK-293 cells, as well as in *Xenopus* oocytes have revealed changes in the expression and/or kinetics of mutant HCN4 channels, but the extent to which especially the kinetic changes would affect *I*~f~ flowing during a human SAN action potential often remains unresolved.

In a previous review, we provided an overview of the *HCN4* and *KCNE2* mutations associated with sinus node dysfunction \[[@B30-ijms-16-03071]\]. This overview was limited to the seven *HCN4* mutations and a single *KCNE2* mutation associated with sinus node dysfunction that were known at that time \[[@B2-ijms-16-03071],[@B19-ijms-16-03071],[@B20-ijms-16-03071],[@B21-ijms-16-03071],[@B22-ijms-16-03071],[@B23-ijms-16-03071],[@B24-ijms-16-03071]\]. Today, however, there are as many as 15 newly discovered *HCN4* variants and mutations \[[@B25-ijms-16-03071],[@B26-ijms-16-03071],[@B27-ijms-16-03071],[@B28-ijms-16-03071]\], some with clinical manifestations beyond sinus node dysfunction, and research is ongoing (e.g., \[[@B31-ijms-16-03071]\]). Here, we first give an overview of these newly discovered *HCN4* variants and mutations and their effects on the characteristics of the HCN4 current. Next, we show how action potentials recorded from isolated human SAN pacemaker cells can be used as the command potential in simulated action potential clamp experiments to assess the effects of *HCN4* mutations on *I*~f~ flowing during a human SAN action potential. Furthermore, we point to apparent inconsistencies between data from clinical studies and data from *in vitro* and *in silico* experiments.

2. Mutations in *HCN4* and *KCNE2* Associated with Sinus Node Dysfunction
=========================================================================

To date, 22 mutations or variants in *HCN4* and one in *KCNE2* have been associated with clinically established or potential sinus node dysfunction \[[@B2-ijms-16-03071],[@B19-ijms-16-03071],[@B20-ijms-16-03071],[@B21-ijms-16-03071],[@B22-ijms-16-03071],[@B23-ijms-16-03071],[@B24-ijms-16-03071],[@B25-ijms-16-03071],[@B26-ijms-16-03071],[@B27-ijms-16-03071],[@B28-ijms-16-03071]\]. [Figure 1](#ijms-16-03071-f001){ref-type="fig"} indicates the location of each of these mutations and variants on the HCN4 and MiRP1 proteins. Clinical observations, if reported, are summarized in [Table 1](#ijms-16-03071-t001){ref-type="table"}, in the order of the mutations and variants on the protein. Changes in expression or kinetic properties associated with the mutations and variants are described below, in the same order, and summarized in [Table 2](#ijms-16-03071-t002){ref-type="table"}. For completeness, previously reviewed mutations \[[@B30-ijms-16-03071]\] are also included. Intriguingly, *HCN4* mutations are not only associated with sinus node dysfunction, but also with AF, left ventricular non-compaction cardiomyopathy (LVNC) and atrioventricular (AV) block.

![Schematic topology of the HCN4 and MiRP1 proteins. The HCN4 α-subunit has six transmembrane segments (S1--S6), a pore-forming loop (P) and intracellular *N*- and *C*-termini. The voltage sensor of the channel is formed by the positively-charged S4 helix. The *C*-terminus comprises the *C*-linker (dotted line) and the cyclic nucleotide-binding domain (cNBD), which is known to mediate cyclic AMP (cAMP)-dependent changes in HCN channel gating. The MiRP1 β-subunit has a single transmembrane segment with an extracellular *N*-terminus and intracellular *C*-terminus. Red dots indicate the location of the 23 known HCN4 and MiRP1 mutation sites associated with clinically established or potential sinus node dysfunction. The split dots indicate the truncations resulting from the 573X and 695X non-sense (truncating) mutations.](ijms-16-03071-g001){#ijms-16-03071-f001}

In our overview, we did not include the *HCN4* mutation in a Brugada syndrome patient described by Ueda *et al.* \[[@B32-ijms-16-03071]\]. The insertion of four bases at a splicing junction of exon 2 and intron 2 likely results in a defective HCN4 protein without the ability to form functional tetramers. A functional analysis in COS-7 cells demonstrated that almost equal amounts of normal and abnormal splicing products were expressed, but *in vitro* electrophysiological data are not available \[[@B32-ijms-16-03071]\]. Furthermore, we did not include the "likely pathogenic" A195V and V759I variants in *HCN4* that were identified by Evans *et al.* \[[@B33-ijms-16-03071]\] in two cases of sudden infant death syndrome (SIDS), because both clinical and *in vitro* data on the effects of these variants are lacking.

A recent abstract mentioned five novel *HCN4* mutations in patients suffering from sinus node dysfunction, dyspnea and AF \[[@B31-ijms-16-03071]\]. Unfortunately, neither the exact mutations nor their effects on the HCN4 current were specified. Thus, these mutations could not be included in our overview.
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###### 

Clinical observations in carriers of mutations in *HCN4* or *KCNE2*.

  Mutation                   Mutation Carriers                                                  Clinical Presentation                                                                                                                                                                                                                                                                                                                                                                   Study
  -------------------------- ------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------
  **Mutations in *HCN4***                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  P257S                      single index patient (65-year-old male)                            diagnosed with paroxysmal AF at age 29; AF became permanent at age 43 years; sinus node dysfunction during ajmaline test in proband and proband's father; 73 pauses \>2.0 s on 24-h Holter monitoring                                                                                                                                                                                   Macri *et al.* \[[@B26-ijms-16-03071]\]
  A414G                      3 members of a single family                                       AF and LVNC in 74-year-old male index patient; combined sinus bradycardia and LVNC in his two mutation-carrying sons; severe sinus bradycardia involving 12 episodes of standstill on Holter monitoring in one of the sons                                                                                                                                                              Milano *et al.* \[[@B27-ijms-16-03071]\]
  G480R                      8 members of a single family                                       asymptomatic sinus bradycardia from a young age, with normal chronotropic and exercise capacity; minimum, average and maximum heart rates of 31 ± 8, 48 ± 12 and 101 ± 21 beats/min, respectively, in the 8 mutation carriers *vs.* 55 ± 9, 73 ± 11 and 126 ± 16 beats/min, respectively, in the 8 non-carriers                                                                         Nof *et al.* \[[@B21-ijms-16-03071]\]
  Y481H                      4 members of two families with a common ancestral haplotype        combined sinus bradycardia and LVNC; frequent episodes of severe bradycardia (heart rate \< 30 beats/min) and pacemaker implantation in the index patient of the first family; severe sinus bradycardia (40 beats/min) in the index patient of the second family and pacemaker implantation in his mutation-carrying mother because of bradyarrhythmias                                 Milano *et al.* \[[@B27-ijms-16-03071]\]
  G482R                      6 members of a single family                                       combined sinus bradycardia and LVNC; pacemaker implanted in three mutation carriers because of bradycardia-related symptoms (average heart rate of 46 beats/min); MVP in two individuals                                                                                                                                                                                                Milano *et al.* \[[@B27-ijms-16-03071]\]
  G482R                      3 members of a single German family                                combined sinus bradycardia, LVNC, and MVP; minimum and average heart rates of 21 and 34 beats/min, respectively, and pacemaker implantation in the index patient                                                                                                                                                                                                                        Schweizer *et al.* \[[@B28-ijms-16-03071]\]
  A485V                      14 members of three Moroccan Jewish decent families                symptomatic familial sinus bradycardia with normal chronotropic and exercise capacity; minimum, average and maximum heart rates of 37 ± 3, 58 ± 6 and 117 ± 27 beats/min in the 14 mutation carriers, respectively, *vs.* 49 ± 11, 77 ± 12 and 140 ± 32 beats/min, respectively, in the 6 non-carriers                                                                                  Laish-Farkash *et al.* \[[@B23-ijms-16-03071]\]
  K530N                      6 members of a single family                                       mild, asymptomatic sinus bradycardia (50--60 beats/min) in the index patient; familial age-dependent tachycardia-bradycardia syndrome and persistent AF; no AF or any other relevant cardiac arrhythmia in non-carriers                                                                                                                                                                 Duhme *et al.* \[[@B24-ijms-16-03071]\]
  D553N                      single index patient (43-year-old female) and two family members   wide spectrum of cardiac arrhythmias, including severe bradycardia (24-h average of 39 beats/min), QT prolongation and *Torsade de Pointes* in the index patient; QT prolongation in family members                                                                                                                                                                                     Ueda *et al.* \[[@B19-ijms-16-03071]\]
  573X                       single index patient (66-year-old female)                          idiopathic sinus bradycardia of 41 beats/min; chronotropic incompetence; intermittent episodes of AF                                                                                                                                                                                                                                                                                    Schulze-Bahr *et al.* \[[@B2-ijms-16-03071]\]
  S672R                      15 members of a single Italian family                              asymptomatic sinus bradycardia; average resting heart rate, corrected for age and gender, of 52.2 ± 1.4 beats/min (range 43--60 beats/min), in the 15 mutation carriers *vs.* 73.2 ± 1.6 beats/min (range 64--81 beats/min) in the 12 non-affected family members                                                                                                                       Milanesi *et al.* \[[@B20-ijms-16-03071]\]
  695X                       8 members of a single German family                                marked sinus bradycardia with no signs of chronotropic incompetence; basal heart rate of 45.9 ± 4.6 beats/min (range 38--51 beats/min) in the 8 mutation carriers *vs.* 66.5 ± 9.1 beats/min in the 6 non-carriers; minimum heart rate of 35.9 ± 5.6 *vs.* 47.2 ± 5.9 beats/min; maximum heart rates of 160.3 ± 12.6 *vs.* 171.8 ± 18.7 beats/min; LVNC in 5 of the mutation carriers   Schweizer *et al.* \[[@B22-ijms-16-03071],[@B28-ijms-16-03071]\]
  P883R                      single male patient                                                sinus bradycardia (35 to 40 beats/min), paroxysmal AF (tachycardia-bradycardia syndrome) and LVNC; pacemaker implantation                                                                                                                                                                                                                                                               Schweizer *et al.* \[[@B28-ijms-16-03071]\]
  G1097W                     single index patient (69-year-old male)                            complete AV block with wide QRS, but no sinus nodal dysfunction; atrial rate of 132 beats/min; ventricular rate of 33 beats/min; pacemaker implantation at the age of 51 years                                                                                                                                                                                                          Zhou *et al.* \[[@B25-ijms-16-03071]\]
  **Mutations in *KCNE2***                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  M54T                       single index patient (55-year-old Caucasian male)                  history of marked sinus bradycardia; average heart rate of 43 beats/min (range 30--125 beats/min), along with pauses; daughter died suddenly at the age of 13, and post-mortem genetic testing revealed the M54T mutation                                                                                                                                                               Nawathe *et al.* \[[@B29-ijms-16-03071]\]

Mutations are heterozygous with autosomal dominant inheritance. AF, atrial fibrillation; LVNC, left ventricular non-compaction cardiomyopathy; MVP, mitral valve prolapse; QT prolongation, prolongation of the rate-corrected QT interval on the electrocardiogram.

2.1. HCN4-K189R
---------------

Macri *et al.* \[[@B26-ijms-16-03071]\] sought to determine if genetic variation in the coding region of *HCN4* is associated with AF. They identified seven novel HCN4 variants in their cohort of 527 unrelated individuals with early-onset AF, as well as three novel variants in their cohort of 443 referent individuals without history or ECG evidence of AF. K189R, located in the *N*-terminus ([Figure 1](#ijms-16-03071-f001){ref-type="fig"}), is one of the HCN4 variants identified in the AF cases. Macri *et al.* \[[@B26-ijms-16-03071]\] overexpressed wild-type and homomeric K189R variant HCN4 channels in CHO cells and carried out voltage-clamp experiments. They did not observe differences in characteristics of the wild-type and variant HCN4 current ([Table 2](#ijms-16-03071-t002){ref-type="table"}). Of note, Macri *et al.* \[[@B26-ijms-16-03071]\] did not study heteromeric wild-type/K189R channels, which would have better resembled the heterozygous condition in individuals carrying the K189R variant.
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###### 

Effect of mutations and variants in *HCN4* or *KCNE2* on HCN4 current.

  Mutation                               Type of Expression   Expression System   Shift in V~1/2~ or Activation Threshold (mV)   Slope Factor (mV)   Time Constant of Activation   Time Constant of Deactivation   Reversal Potential   Full-Activated Current Density   Channel Expression   Sensitivity to cAMP                               Reference
  -------------------------------------- -------------------- ------------------- ---------------------------------------------- ------------------- ----------------------------- ------------------------------- -------------------- -------------------------------- -------------------- ------------------------------------------------- -------------------------------------------------
  **Mutations and Variants in *HCN4***                                                                                                                                                                                                                                                                                                          
  K189R                                  homomeric            CHO                 =                                              =                   ?                             ?                               ?                    =                                ?                    ?                                                 Macri *et al.* \[[@B26-ijms-16-03071]\]
  P257S                                  heteromeric          CHO                 =                                              =                   ?                             ?                               ?                    =                                ≈50%                 ?                                                 Macri *et al.* \[[@B26-ijms-16-03071]\]
  homomeric                              CHO                                                                                                                                                                       0%                   ↓                                                     Macri *et al.* \[[@B26-ijms-16-03071]\]           
  A414G                                  heteromeric          CHO                 −23.9                                          =                   ?                             ?                               ?                    =                                ?                    ?                                                 Milano *et al.* \[[@B27-ijms-16-03071]\]
  G480R                                  heteromeric          oocyte, HEK         ≈−15                                           ?                   ↑ ^a^                         ?                               =                    ≈50%                             ?                    = ^b^                                             Nof *et al.* \[[@B21-ijms-16-03071]\]
  homomeric                              oocyte, HEK          ≈−30                ?                                              ↑ ^a^               ?                             =                               ≈12%                 ↓                                = ^b^                Nof *et al.* \[[@B21-ijms-16-03071]\]             
                                         oocyte               ?                   ?                                              ?                   ?                             ?                               ≈20%                 ?                                ?                    Laish-Farkash *et al.* \[[@B23-ijms-16-03071]\]   
  Y481H                                  heteromeric          CHO                 −43.9                                          =                   ?                             ?                               ?                    =                                ?                    ?                                                 Milano *et al.* \[[@B27-ijms-16-03071]\]
  G482R                                  heteromeric          HEK                 =                                              =                   =                             =                               =                    35%                              =                    ?                                                 Schweizer *et al.* \[[@B28-ijms-16-03071]\]
                                         CHO                  −38.7               =                                              ?                   ?                             ?                               =                    ?                                ?                    Milano *et al.* \[[@B27-ijms-16-03071]\]          
  homomeric                              HEK                  ?                   ?                                              ?                   ?                             ?                               6%                   =                                ?                    Schweizer *et al.* \[[@B28-ijms-16-03071]\]       
  A485V                                  heteromeric          oocyte, HEK         ≈−30                                           ?                   ↑ ^a^                         ↑ ^a^                           =                    ≈33%                             =                    ?                                                 Laish-Farkash *et al.* \[[@B23-ijms-16-03071]\]
  homomeric                              oocyte, HEK          ≈−60                ?                                              ↑ ^a^               ↑ ^a^                         =                               ≈5%                  =                                ↓                    Laish-Farkash *et al.* \[[@B23-ijms-16-03071]\]   
  K530N                                  heteromeric          HEK                 ≈−14                                           =                   237%                          =                               =                    =                                ?                    ↑                                                 Duhme *et al.* \[[@B24-ijms-16-03071]\]
  homomeric                              HEK                  =                   =                                              =                   =                             =                               =                    ?                                =                    Duhme *et al.* \[[@B24-ijms-16-03071]\]           
  D553N                                  heteromeric          COS                 =                                              =                   ≈90%                          ≈110%                           ?                    ≈37%                             ↓                    ?                                                 Ueda *et al.* \[[@B19-ijms-16-03071]\]
                                         oocyte, COS          ?                   ?                                              ?                   ?                             ?                               ≈54%                 =                                ?                    Netter *et al.* \[[@B34-ijms-16-03071]\]          
  homomeric                              COS                  =                   =                                              ≈90%                ≈110%                         ?                               ≈8%                  ↓                                ?                    Ueda *et al.* \[[@B19-ijms-16-03071]\]            
                                         oocyte, COS          =                   =                                              =                   =                             ?                               ≈12%                 =                                ↓                    Netter *et al.* \[[@B34-ijms-16-03071]\]          
  573X                                   heteromeric          COS                 = ^c^                                          −1.9 ^c^            =                             ?                               ?                    ?                                =                    ↓                                                 Schulze-Bahr *et al.* \[[@B2-ijms-16-03071]\]
  homomeric                              COS                  −4.6 ^c^            =                                              =                   ? ^a^                         ?                               ?                    =                                ↓                    Schulze-Bahr *et al.* \[[@B2-ijms-16-03071]\]     
  S672R                                  heteromeric          HEK                 −4.9                                           =                   =                             ≈74%                            ?                    ?                                ?                    ?                                                 Milanesi *et al.* \[[@B20-ijms-16-03071]\]
  homomeric                              HEK                  −8.4                =                                              =                   ≈63%                          ?                               ?                    ?                                =                    Milanesi *et al.* \[[@B20-ijms-16-03071]\]        
                                         oocyte               −6.1                ?                                              ≈180%               ≈90%                          ?                               ?                    ?                                ↓                    Xu *et al.* \[[@B32-ijms-16-03071]\]              
  N688S                                  homomeric            CHO                 =                                              =                   ?                             ?                               ?                    =                                ?                    ?                                                 Macri *et al.* \[[@B26-ijms-16-03071]\]
  695X                                   heteromeric          HEK                 =                                              =                   =                             ?                               ?                    =                                ?                    ↓                                                 Schweizer *et al.* \[[@B22-ijms-16-03071]\]
  homomeric                              HEK                  =                   −3.5                                           72%                 =                             =                               ?                    ?                                ↓                    Schweizer *et al.* \[[@B22-ijms-16-03071]\]       
  T822M                                  homomeric            CHO                 =                                              =                   ?                             ?                               ?                    =                                ?                    ?                                                 Macri *et al.* \[[@B26-ijms-16-03071]\]
  G885R                                  homomeric            CHO                 =                                              =                   ?                             ?                               ?                    =                                ?                    ?                                                 Macri *et al.* \[[@B26-ijms-16-03071]\]
  P945S                                  homomeric            CHO                 =                                              =                   ?                             ?                               ?                    =                                ?                    ?                                                 Macri *et al.* \[[@B26-ijms-16-03071]\]
  A1045V                                 homomeric            CHO                 =                                              =                   ?                             ?                               ?                    =                                ?                    ?                                                 Macri *et al.* \[[@B26-ijms-16-03071]\]
  R1068H                                 homomeric            CHO                 =                                              =                   ?                             ?                               ?                    =                                ?                    ?                                                 Macri *et al.* \[[@B26-ijms-16-03071]\]
  G1077S                                 homomeric            CHO                 =                                              =                   ?                             ?                               ?                    =                                ?                    ?                                                 Macri *et al.* \[[@B26-ijms-16-03071]\]
  G1097W                                 heteromeric          CHO                 −7.6                                           =                   ?                             81%                             ?                    55%                              ?                    ?                                                 Zhou *et al.* \[[@B25-ijms-16-03071]\]
  homomeric                              CHO                  −12                 =                                              ?                   79%                           ?                               47%                  ?                                =                    Zhou *et al.* \[[@B25-ijms-16-03071]\]            
  E1193Q                                 homomeric            CHO                 =                                              =                   ?                             ?                               ?                    =                                ?                    ?                                                 Macri *et al.* \[[@B26-ijms-16-03071]\]
  **Mutations in*KCNE2***                                                                                                                                                                                                                                                                                                                       
  M54T                                   homomeric            NRVM                =                                              =                   192%                          =                               ?                    18%                              ?                    ?                                                 Nawathe *et al.* \[[@B29-ijms-16-03071]\]

Data are the changes relative to wild-type current. ?, not reported; ≈, estimated from presented figures; ↓, decreased; ↑, increased; =, unchanged. ^a^ Changes reported, but no quantitative data provided; ^b^ performed in oocytes, which lack cAMP modulation, due to high basal activity \[[@B21-ijms-16-03071]\]; ^c^ with 15-s hyperpolarizing pulses (at 20--22 °C); oocyte, HEK, COS and NRVM: *Xenopus* oocytes, HEK-293 cells, COS-7 cells and neonatal rat ventricular cardiomyocytes, respectively.

2.2. HCN4-P257S
---------------

Like the above K189R variant, P257S, also located in the *N*-terminus ([Figure 1](#ijms-16-03071-f001){ref-type="fig"}), is one of the seven HCN4 variants identified by Macri *et al.* \[[@B26-ijms-16-03071]\] in their cohort of individuals with early-onset AF. Expression of homomeric P257S-variant HCN4 channels in CHO cells did not result in any measurable HNC4 current in voltage-clamp experiments, whereas co-expression of wild-type and variant HCN4 did not reveal any changes with respect to wild-type HNC4 current ([Table 2](#ijms-16-03071-t002){ref-type="table"}). However, with the use of immunocytochemistry and confocal microscopy, Macri *et al.* \[[@B26-ijms-16-03071]\] also demonstrated that P257S variant channels were not detectable at the plasma membrane, but instead were retained in the cytoplasm, which suggests that the P257S variant disrupts trafficking to the cell membrane. Macri *et al.* \[[@B26-ijms-16-03071]\] further demonstrated that, when co-expressed, wild-type HCN4 channels do not colocalize with P257S variant channels at the cell membrane. The latter findings suggest, despite the similar current density in voltage-clamp experiments ([Table 2](#ijms-16-03071-t002){ref-type="table"}), that the P257S variant may be related to the clinically observed AF ([Table 1](#ijms-16-03071-t001){ref-type="table"}) as a result of haploinsufficiency, with only the single wild-type allele contributing to the production of the HCN4 channel protein and current.

2.3. HCN4-A414G
---------------

A414G is a mutation in the S4--S5 linker ([Figure 1](#ijms-16-03071-f001){ref-type="fig"}) associated with sinus bradycardia, AF and LVNC in three members of a single family ([Table 1](#ijms-16-03071-t001){ref-type="table"}). Functional analysis in CHO cells revealed a significant hyperpolarizing shift in the voltage dependence of activation of heteromerically expressed A414G mutant HCN4 channels ([Table 2](#ijms-16-03071-t002){ref-type="table"}). This shift resulted in a dramatic decrease of the fully-activated HCN4 current density in the voltage range of the diastolic depolarization of SAN cells \[[@B27-ijms-16-03071]\].

2.4. HCN4-G480R
---------------

G480R is one of the currently known mutations in the pore-forming loop of the HCN4 protein ([Figure 1](#ijms-16-03071-f001){ref-type="fig"}). It is associated with asymptomatic sinus bradycardia from a young age, with normal chronotropic and exercise capacity ([Table 1](#ijms-16-03071-t001){ref-type="table"}). Western blot analysis demonstrated significantly reduced membrane expression of homomeric HCN4-G480R channels in HEK-293 cells \[[@B21-ijms-16-03071]\]. Functional analysis in *Xenopus* oocytes and HEK-293 cells revealed a decrease in fully-activated current density, accompanied by a hyperpolarizing shift in the voltage dependence of activation and slowing of activation kinetics ([Table 2](#ijms-16-03071-t002){ref-type="table"}). In *Xenopus* oocytes, neither wild-type nor G480R currents were modulated by β-adrenergic regulation, likely due to the high levels of endogenous cyclic AMP (cAMP) in *Xenopus* oocytes \[[@B35-ijms-16-03071]\]. Thus, whether the G480R mutation affects the sensitivity to cAMP is unresolved. Laish-Farkash *et al.* \[[@B23-ijms-16-03071]\] later confirmed the decrease of fully-activated current density in HEK-293 cells.

2.5. HCN4-Y481H
---------------

Another, recently discovered mutation in the pore-forming loop of the HCN4 protein is Y481H ([Figure 1](#ijms-16-03071-f001){ref-type="fig"}). It is associated with combined sinus bradycardia and LVNC in four members of two families with a common ancestral haplotype ([Table 1](#ijms-16-03071-t001){ref-type="table"}). If heteromerically expressed in CHO cells, the Y481H mutation results in a \>40-mV shift in the voltage dependence of activation towards more negative potentials ([Table 2](#ijms-16-03071-t002){ref-type="table"}). As a consequence, the fully-activated HCN4 current density in the voltage range of diastolic depolarization of SAN cells is almost zero \[[@B27-ijms-16-03071]\].

2.6. HCN4-G482R
---------------

Recently, both Milano *et al.* \[[@B27-ijms-16-03071]\] and Schweizer *et al.* \[[@B28-ijms-16-03071]\] reported an association of the G482R mutation with combined sinus bradycardia and LVNC in a total of nine individuals from two families ([Table 1](#ijms-16-03071-t001){ref-type="table"}). Like the above G480R and Y481H mutations, the G482R mutation is located in the pore-forming loop of the HCN4 protein ([Figure 1](#ijms-16-03071-f001){ref-type="fig"}). Patch-clamp experiments in HEK-293 cells by Schweizer *et al.* \[[@B28-ijms-16-03071]\] demonstrated that homomeric G482R mutant channels were non-functional, despite similar surface expression of HCN4 wild-type and mutant subunits. In case of heteromeric expression, the mutation exerted dominant negative effects as revealed by a 65% reduction in fully-activated current density, without affecting the voltage dependence of activation. Milano *et al.* \[[@B27-ijms-16-03071]\], on the other hand, reported a strong hyperpolarizing shift in the voltage dependence of activation of G482R channels that were heteromerically expressed in CHO cells, resulting in a negligible fully-activated HCN4 current density in the voltage range of diastolic depolarization of SAN cells.

2.7. HCN4-A485V
---------------

Laish-Farkash *et al.* \[[@B23-ijms-16-03071]\] observed familial sinus bradycardia in 14 members of three Moroccan Jewish decent families carrying the A485V mutation, which is another mutation in the pore-forming loop ([Figure 1](#ijms-16-03071-f001){ref-type="fig"}). Western blot analysis revealed significantly reduced membrane expression of homomeric A485V mutant channels in HEK-293 cells \[[@B23-ijms-16-03071]\]. Functional analysis of both homomerically and heteromerically expressed mutant channels in *Xenopus* oocytes and HEK-293 cells demonstrated large hyperpolarizing shifts of the voltage dependence of activation, slowing of both activation and deactivation, and a reduction in fully-activated current density ([Table 2](#ijms-16-03071-t002){ref-type="table"}).

2.8. HCN4-K530N
---------------

Tachycardia-bradycardia syndrome and persistent AF were observed in six members of a single family carrying the K530N mutation in *HCN4* \[[@B24-ijms-16-03071]\], located in the *C*-linker of the HCN4 protein ([Figure 1](#ijms-16-03071-f001){ref-type="fig"}). Patch-clamp experiments in HEK-293 cells revealed similar characteristics of wild-type channels and homomerically expressed mutant channels ([Table 2](#ijms-16-03071-t002){ref-type="table"}). However, experiments on heteromerically expressed channels demonstrated a hyperpolarizing shift of the half-maximal activation voltage and slowed activation of the HCN4 current. Furthermore, heteromeric channels showed a larger sensitivity to cAMP than either homomeric mutant or wild-type channels, as demonstrated by the ≈7-mV larger cAMP-induced shift of the activation curve and the larger change in the activation time constant.

2.9. HCN4-D553N
---------------

Also located in the *C*-linker is the D553N mutation ([Figure 1](#ijms-16-03071-f001){ref-type="fig"}). Several electrophysiological abnormalities, including severe bradycardia and QT prolongation (*i.e.*, prolongation of the rate-corrected QT interval on the electrocardiogram), were noticed in three members of a single family carrying this mutation \[[@B24-ijms-16-03071]\]. A functional study in COS-7 cells \[[@B19-ijms-16-03071]\] showed a reduced membrane expression and decreased current, because of a dominant-negative trafficking defect of the D553N mutant protein. The voltage dependence of activation of the mutant HCN4 channel was comparable to the wild-type, but activation was slightly faster, while deactivation was slightly slower ([Table 2](#ijms-16-03071-t002){ref-type="table"}). On the other hand, Netter *et al.* \[[@B34-ijms-16-03071]\] reported that D553N mutant channels have normal trafficking, with similar surface expression of D553N and wild-type channels in COS-7, HeLa and HL-1 cells. In both *Xenopus* oocytes and COS-7 cells, D553N channels generated currents with reduced amplitude, but unaltered kinetics. Furthermore, homomeric D553N channels did not respond to adrenergic stimulation.

2.10. HCN4-573X
---------------

In a single index patient, Schulze-Bahr *et al.* \[[@B2-ijms-16-03071]\] observed sinus bradycardia with chronotropic incompetence and episodes of AF ([Table 1](#ijms-16-03071-t001){ref-type="table"}). This patient carried the 573X non-sense (truncating) mutation in the *C*-linker ([Figure 1](#ijms-16-03071-f001){ref-type="fig"}). The mutation thus resulted in a truncated HCN4 protein that lacks the cyclic nucleotide-binding domain (cNBD), which mediates the cAMP effects on gating of the HCN4 channel. In COS-7 cells, mutant subunits showed normal intracellular trafficking and integration into the cell membrane \[[@B2-ijms-16-03071]\]. Patch-clamp experiments demonstrated a steeper steady-state activation curve with a shift to more hyperpolarized potentials, but this required excessively long hyperpolarizing voltage steps to become apparent ([Table 2](#ijms-16-03071-t002){ref-type="table"}). Both homomeric and heteromeric channels appeared insensitive to cAMP, demonstrating a dominant-negative effect of the mutant on wild-type subunits.

2.11. HCN4-S672R
----------------

Fifteen carriers of the S672R mutation, all members of a single Italian family, showed asymptomatic sinus bradycardia ([Table 1](#ijms-16-03071-t001){ref-type="table"}). A functional study in HEK-293 cells revealed a shift in channel activation to more hyperpolarized potentials and faster deactivation of both homomeric and heteromeric mutant channels ([Table 2](#ijms-16-03071-t002){ref-type="table"}). The cAMP-dependent shifts in voltage dependence of activation, as assessed in inside-out macropatches, were similar in wild-type and homomeric mutant channels \[[@B20-ijms-16-03071]\], suggesting that the S672R mutation did not affect the sensitivity to cAMP, notwithstanding its location in the cNBD ([Figure 1](#ijms-16-03071-f001){ref-type="fig"}). Xu *et al.* \[[@B36-ijms-16-03071]\], on the other hand, made inside-out patch-clamp recordings in *Xenopus* oocytes and found a reduced sensitivity to cAMP, which, however, was challenged in a review by DiFrancesco \[[@B7-ijms-16-03071]\].

2.12. HCN4-N688S
----------------

The N688S variant is also located in the cNBD of the HCN4 subunit ([Figure 1](#ijms-16-03071-f001){ref-type="fig"}). It is one of the three novel variants that Macri *et al.* \[[@B26-ijms-16-03071]\] observed in their cohort of 443 referent individuals without history or ECG evidence of AF. In patch-clamp experiments on CHO cells, no functional effects of the N688S variant were observed ([Table 2](#ijms-16-03071-t002){ref-type="table"}). Of note, preservation of cAMP dependence was not assessed.

2.13. HCN4-695X
---------------

In a single German family, Schweizer *et al.* \[[@B22-ijms-16-03071]\] observed marked sinus bradycardia without signs of chronotropic incompetence in eight carriers of the 695X non-sense mutation in *HCN4* ([Table 1](#ijms-16-03071-t001){ref-type="table"}). Recently, Schweizer *et al.* \[[@B28-ijms-16-03071]\] reported LVNC in five of the eight mutation carriers. Like the above 573X mutation, the 695X mutation results in a truncated cNBD ([Figure 1](#ijms-16-03071-f001){ref-type="fig"}). Patch-clamp experiments in HEK-293 cells demonstrated a steeper slope of the activation curve and faster activation of homomeric 695X mutant current, as well as insensitivity to cAMP ([Table 2](#ijms-16-03071-t002){ref-type="table"}). Heteromeric channels failed to respond to cAMP, like homomeric mutant channels, indicating a dominant-negative suppression of cAMP responsiveness by the mutant subunits, notwithstanding the apparent absence of signs of chronotropic incompetence in the mutation carriers.

2.14. HCN4-T822M
----------------

The T822M variant, located in the distal *C*-terminus beyond the cNBD ([Figure 1](#ijms-16-03071-f001){ref-type="fig"}), is one of the seven novel variants that Macri *et al.* \[[@B26-ijms-16-03071]\] observed in their cohort of 527 unrelated individuals with early-onset AF. In patch-clamp experiments on CHO cells, no functional effects of the T822M variant were observed ([Table 2](#ijms-16-03071-t002){ref-type="table"}).

2.15. HCN4-P883R
----------------

The P883R mutation in *HCN4* was found by Schweizer *et al.* \[[@B28-ijms-16-03071]\] in a single patient who showed sinus bradycardia, tachycardia-bradycardia syndrome and LVNC and who required pacemaker implantation. Unfortunately, patch-clamp data on the P883R mutant channel are not available. The mutation is therefore not included in [Table 2](#ijms-16-03071-t002){ref-type="table"}.

2.16. HCN4-G885R, -P945S, -A1045V, -R1068H and -G1077S
------------------------------------------------------

Like the T822M variant, the G885R, P945S, A1045V, R1068H and G1077S variants, which are all located in the distal *C*-terminus beyond the cNBD ([Figure 1](#ijms-16-03071-f001){ref-type="fig"}), are novel HCN4 variants that Macri *et al.* \[[@B26-ijms-16-03071]\] observed in their cohort of 527 unrelated individuals with early-onset AF (G885R, P945S and G1077S) or in their cohort of 443 referent individuals without history or ECG evidence of AF (A1045V and R1068H). In patch-clamp experiments on CHO cells, none of the five variants showed functional effects ([Table 2](#ijms-16-03071-t002){ref-type="table"}).

2.17. HCN4-G1097W
-----------------

Zhou *et al.* \[[@B25-ijms-16-03071]\] observed the G1097W mutation in a single index patient with AV block, but not sinus nodal dysfunction ([Table 1](#ijms-16-03071-t001){ref-type="table"}). In patch-clamp experiments on CHO cells, both homomeric and heteromeric channels demonstrated a hyperpolarizing shift in the voltage dependence of activation, a reduced fully-activated current density and a faster deactivation ([Table 2](#ijms-16-03071-t002){ref-type="table"}). The sensitivity to intracellular cAMP, as assessed for homomeric channels, was not affected.

2.18. HCN4-E1193Q
-----------------

The E1193Q variant, located near the end of the *C*-terminus of the HCN4 protein ([Figure 1](#ijms-16-03071-f001){ref-type="fig"}), is one of the seven novel HCN4 variants that Macri *et al.* \[[@B26-ijms-16-03071]\] observed in their cohort of 527 unrelated individuals with early-onset AF. Patch-clamp experiments on CHO cells did not reveal any functional effects of the variant ([Table 2](#ijms-16-03071-t002){ref-type="table"}).

2.19. KCNE2-M54T
----------------

Nawathe *et al.* \[[@B29-ijms-16-03071]\] reported marked sinus bradycardia, along with pauses, in a single index patient who carried the M54T mutation in *KCNE2* ([Table 1](#ijms-16-03071-t001){ref-type="table"}). The mutation is in the transmembrane segment of the *KCNE2*-encoded MiRP1 protein ([Figure 1](#ijms-16-03071-f001){ref-type="fig"}). Patch-clamp experiments in neonatal rat ventricular myocytes demonstrated that co-expression with M54T MiRP1 decreased HCN4 current density by \>80% compared to HCN4 alone or HCN4 co-expressed with wild-type MiRP1. Furthermore, co-expression with M54T MiRP1 slowed HCN4 activation at physiologically relevant voltages, while HCN4 deactivation and the voltage dependence of activation were not affected ([Table 2](#ijms-16-03071-t002){ref-type="table"}).

3. Functional Effects of Novel *HCN4* Mutations on Human *I*~f~
===============================================================

In our previous review \[[@B30-ijms-16-03071]\], we assessed the functional effects of the then known *HCN4* and *KCNE2* mutations on human *I*~f~ through simulated action potential clamp experiments. Action potentials recorded from single, isolated human SAN cells \[[@B37-ijms-16-03071]\] were used as command potentials, and *I*~f~ was simulated using mathematical equations based on the voltage clamp data that we had acquired from single, isolated human SAN cells \[[@B38-ijms-16-03071],[@B39-ijms-16-03071]\]. Thus, we reconstructed *I*~f~ during the time course of a human SAN action potential. Here, we apply this approach to the aforementioned P257S, A414G, Y481H, G482R and G1097W mutations in *HCN4*. We selected these five mutations, because they were not included in our previous review, they have clinically established effects ([Table 1](#ijms-16-03071-t001){ref-type="table"}), and patch-clamp data on heteromerically expressed mutant channels, resembling the heterozygous mutation carrier situation, are available ([Table 2](#ijms-16-03071-t002){ref-type="table"}).

3.1. Numerical Reconstruction of I~f~
-------------------------------------

[Figure 2](#ijms-16-03071-f002){ref-type="fig"}A shows the action potentials that were used, as part of a train of action potentials, in the simulated action potential clamp experiments. The associated rate of change of the membrane potential (d*V*~m~/d*t*) is shown in [Figure 2](#ijms-16-03071-f002){ref-type="fig"}B, whereas a recording of the global intracellular calcium concentration (\[Ca^2+^\]~i~), from a different cell with virtually the same cycle length \[[@B40-ijms-16-03071]\], is shown in [Figure 2](#ijms-16-03071-f002){ref-type="fig"}C. With these data, the ion current traces of [Figure 2](#ijms-16-03071-f002){ref-type="fig"}D could be reconstructed, focusing on the diastolic depolarization phase. The noisy grey trace shows the net membrane current (*I*~net~), as computed from *I*~net~ = −*C*~m~ × d*V*~m~/d*t*, where d*V*~m~/d*t* is taken from [Figure 2](#ijms-16-03071-f002){ref-type="fig"}B, and *C*~m~ and *V*~m~ denote the membrane capacitance and membrane potential, respectively. The orange and green traces of [Figure 2](#ijms-16-03071-f002){ref-type="fig"}D show the L-type calcium current (*I*~Ca,L~) and delayed rectifier potassium current (*I*~Kr~), respectively, which, together with *I*~f~ (blue trace), supposedly constitute the main voltage-dependent ion currents during diastolic depolarization. [Figure 2](#ijms-16-03071-f002){ref-type="fig"}D illustrates the importance of *I*~f~ as a pacemaker current, generating an inward current during diastolic depolarization of similar amplitude as *I*~net~. It should, however, be kept in mind that *I*~net~ is the net result of multiple inward and outward currents, including *I*~Ca,L~ and *I*~Kr~, which may interact in a complex manner \[[@B4-ijms-16-03071]\].

![Membrane currents of a human sinoatrial node (SAN) pacemaker cell assessed by a simulated action potential clamp. (**A**) Action potentials recorded from a human SAN pacemaker cell used for the action potential clamp; (**B**) associated rate of change of the membrane potential (d*V*~m~/d*t*); (**C**) global intracellular calcium concentration (\[Ca^2+^\]~i~) in a different cell with a highly similar cycle length; and (**D**) numerically reconstructed membrane current (*I*~m~): L-type calcium current (*I*~Ca,L~), *I*~f~, delayed rectifier potassium current (*I*~Kr~) and net membrane current (*I*~net~). See the text for details.](ijms-16-03071-g002){#ijms-16-03071-f002}

For the numerical reconstruction of *I*~Ca,L~ and *I*~Kr~, we followed the approach of Chandler *et al.* \[[@B11-ijms-16-03071]\], who used the equations of the Courtemanche *et al.* \[[@B41-ijms-16-03071]\] human atrial cell model, scaled down by 32% and 55%, respectively, in accordance with the relative abundance (human sinus node *vs.* human right atrium) of mRNAs responsible for the *I*~Ca,L~ and *I*~Kr~ ion channels. *I*~Kr~ could be reconstructed with the train of action potentials of [Figure 2](#ijms-16-03071-f002){ref-type="fig"}A, but for the reconstruction of *I*~Ca,L~, we also needed the \[Ca^2+^\]~i~ data of [Figure 2](#ijms-16-03071-f002){ref-type="fig"}C, because the inactivation kinetics of this current are not only voltage dependent, but also calcium dependent. For the numerical reconstruction of *I*~f~, we used the mathematical equations that we previously derived from the voltage clamp data that we had acquired from single, isolated human SAN pacemaker cells \[[@B38-ijms-16-03071],[@B39-ijms-16-03071]\].

[Figure 3](#ijms-16-03071-f003){ref-type="fig"} shows the effects of mutations in *HCN4* on *I*~f~, both under control conditions (blue traces) and upon adrenergic stimulation (red traces). In the absence of action potentials recorded upon adrenergic stimulation, the same train of action potentials ([Figure 3](#ijms-16-03071-f003){ref-type="fig"}A) was used to reconstruct *I*~f~ in the case of elevated cAMP levels. This was achieved by repeating the simulations with the activation and time constant curves shifted by +15 mV \[[@B30-ijms-16-03071]\]. The resulting *I*~f~ trace is shown as a solid red line in [Figure 3](#ijms-16-03071-f003){ref-type="fig"}B. It is immediately apparent from [Figure 3](#ijms-16-03071-f003){ref-type="fig"}B that the amplitude of *I*~f~ is more than doubled upon adrenergic stimulation.

To quantify the contribution of *I*~f~ to diastolic depolarization, we computed the charge carried by *I*~f~ (*Q*~f~) during the 25-mV, 550-ms depolarization that starts at the maximum diastolic potential of −63 mV ([Figure 3](#ijms-16-03071-f003){ref-type="fig"}A, double-headed arrow). Under control conditions, *Q*~f~ amounts to 0.018 pC/pF ([Figure 4](#ijms-16-03071-f004){ref-type="fig"}, leftmost blue bar), which is somewhat smaller than the net charge flow of 0.025 pC/pF or, equivalently, 25 mV ([Figure 4](#ijms-16-03071-f004){ref-type="fig"}, dashed grey line). Upon adrenergic stimulation, *Q*~f~ increases 2.4-fold to 0.042 pC/pF ([Figure 4](#ijms-16-03071-f004){ref-type="fig"}, leftmost red bar). Thus, one might say that wild-type *I*~f~ has a "depolarization reserve" of 24 mV, *i.e.*, the difference between the "depolarization power" of 18 mV under basal conditions and 42 mV upon adrenergic stimulation.

To simulate the effects of the mutations, we adapted the *I*~f~ parameter settings for the mutation of interest according to the data presented in [Table 2](#ijms-16-03071-t002){ref-type="table"}. Thus, the P257S mutation is simulated through a 50% reduction in the fully-activated conductance of *I*~f~, whereas the A414G mutation is simulated through a −23.9 mV shift in its voltage dependence, *etc*. The parameter settings for each of the aforementioned novel mutations in *HCN4*, all expressed as changes relative to the wild-type, are listed in [Table 3](#ijms-16-03071-t003){ref-type="table"}, together with the parameter settings that we applied in our previous review to simulate the then known mutations in *HCN4* and *KCNE2*.

3.2. HCN4-P257S
---------------

In the case of the P257S mutation, there is no shift in voltage dependence. Furthermore, sensitivity to cAMP is not affected. However, the current density of heteromeric P257S channels is reduced to ≈50% ([Table 2](#ijms-16-03071-t002){ref-type="table"}). Accordingly, we reduced the fully-activated conductance of *I*~f~ to 50% of the wild-type, which of course leads to an equivalent reduction in the *I*~f~ amplitude ([Figure 3](#ijms-16-03071-f003){ref-type="fig"}C) and *Q*~f~ ([Figure 4](#ijms-16-03071-f004){ref-type="fig"}A), both under control conditions and upon adrenergic stimulation. One may question whether these relatively mild functional effects are the main cause of the AF and (hidden) sinus node dysfunction observed in the single index patient.

3.3. HCN4-A414G
---------------

In the case of the A441G mutation, there is a \>20-mV hyperpolarizing shift in the voltage dependence of the *I*~f~ kinetics. As a result, *I*~f~ is significantly reduced throughout diastole ([Figure 3](#ijms-16-03071-f003){ref-type="fig"}D), and the charge carried by *I*~f~ is reduced to 20% of the wild-type under control conditions and 24% upon adrenergic stimulation ([Figure 4](#ijms-16-03071-f004){ref-type="fig"}A). These functional effects may underlie the sinus bradycardia observed in the mutation-carrying family ([Table 1](#ijms-16-03071-t001){ref-type="table"}).

![Effect of mutations in *HCN4* on *I*~f~ in a human SAN pacemaker cell assessed by simulated action potential clamp. (**A**) Action potentials recorded from a human SAN pacemaker cell used for action potential clamp; (**B**) computed wild-type (WT) *I*~f~ of a human SAN pacemaker cell during the action potentials of (**A**) under control conditions ("control", blue line) and upon adrenergic stimulation ("cAMP", red line); (**C**--**H**) computed *I*~f~ of a human SAN pacemaker cell carrying heterozygous mutation in *HCN4*, as indicated, during the action potentials of (**A**) under control conditions (solid blue line) and upon adrenergic stimulation (solid red line). Wild-type *I*~f~ of (**B**) under control conditions (dashed blue line) and upon adrenergic stimulation (dashed red line) are shown for reference. G482R traces, labelled "a" and "b", are based on data from Milano *et al.* \[[@B27-ijms-16-03071]\] and Schweizer *et al.* \[[@B28-ijms-16-03071]\], respectively.](ijms-16-03071-g003){#ijms-16-03071-f003}

![Contribution of *I*~f~ to diastolic depolarization for each of the heterozygous mutations in *HCN4* or *KCNE2*. The charge carried by *I*~f~ (*Q*~f~) during the 25-mV, 550-ms spontaneous depolarization from the maximum diastolic potential of −63 mV of the human SAN action potential is as indicated in [Figure 3](#ijms-16-03071-f003){ref-type="fig"}A. The blue bars are computed from the *I*~f~ traces under control conditions ("control"). The red bars are computed from the *I*~f~ traces upon adrenergic stimulation ("cAMP"). The dashed grey line indicates the charge of 0.025 pC/pF carried by the net membrane current (*Q*~net~) during the 25-mV depolarization. (**A**) Mutations of [Figure 3](#ijms-16-03071-f003){ref-type="fig"}; (**B**) mutations assessed in previous publication \[[@B30-ijms-16-03071]\].](ijms-16-03071-g004){#ijms-16-03071-f004}

ijms-16-03071-t003_Table 3

###### 

Parameter settings in simulated action potential clamp experiments.

  Mutation           Scaling Factor for *I*~f~ Conductance   Shift (mV)   Shift with cAMP (mV)
  ------------------ --------------------------------------- ------------ ----------------------
  *HCN4*-P257S       0.50                                    0            +15
  *HCN4*-A414G       1                                       −23.9        −8.9
  *HCN4*-G480R       0.50                                    −15          0
  *HCN4*-Y481H       1                                       −43.9        −28.9
  *HCN4*-G482R ^a^   1                                       −38.7        −23.7
  *HCN4*-G482R ^b^   0.35                                    0            +15
  *HCN4*-A485V       0.33                                    −30          −15
  *HCN4*-K530N       1                                       −14          +7.8
  *HCN4*-D553N       0.37                                    0            +15
  *HCN4*-573X        1                                       0            0
  *HCN4*-S672R       1                                       −4.9         +10.1
  *HCN4*-695X        1                                       0            0
  *HCN4*-G1097W      0.55                                    −7.6         +7.4
  *KCNE2*-M54T       0.18                                    0            +15

Scaling factor and shifts relative to the wild-type. Shifts applied to both the steady-state activation curve and time constant curve. ^a^ According to Milano *et al.* \[[@B27-ijms-16-03071]\]; ^b^ according to Schweizer *et al.* \[[@B28-ijms-16-03071]\].

3.4. HCN4-Y481H
---------------

*I*~f~ is dramatically reduced in the case of the Y481H mutation, which causes a \>40-mV hyperpolarizing shift in the voltage dependence of the *I*~f~ kinetics ([Figure 3](#ijms-16-03071-f003){ref-type="fig"}E). This is reflected in the charge carried by *I*~f~ during diastole, which amounts to only 5%--6% of the wild-type ([Figure 4](#ijms-16-03071-f004){ref-type="fig"}A). This dramatic functional effect seems compatible with the severe bradycardia in the Y481H mutation carriers ([Table 1](#ijms-16-03071-t001){ref-type="table"}).

3.5. HCN4-G482R
---------------

A severe bradycardia is also observed in carriers of the G482R mutation ([Table 1](#ijms-16-03071-t001){ref-type="table"}). In line, *I*~f~ is dramatically reduced ([Figure 3](#ijms-16-03071-f003){ref-type="fig"}F), with a *Q*~f~ of only 7%--9% of the wild-type ([Figure 4](#ijms-16-03071-f004){ref-type="fig"}A), if we base our simulations on the patch-clamp data by Milano *et al.* \[[@B27-ijms-16-03071]\], which show a very strong hyperpolarizing shift in the voltage dependence of *I*~f~. However, patch-clamp data on the same mutation by Schweizer *et al.* \[[@B28-ijms-16-03071]\] do show a 65% reduction in the fully-activated conductance of *I*~f~, rather than a shift in its voltage dependence. If we base our simulations on the latter data, we of course obtain a 65% reduction in *I*~f~ amplitude ([Figure 3](#ijms-16-03071-f003){ref-type="fig"}G) and *Q*~f~ ([Figure 4](#ijms-16-03071-f004){ref-type="fig"}A), both under control conditions and upon adrenergic stimulation.

3.6. HCN4-G1097W
----------------

With the combined effect of a shift in voltage dependence and a 45% reduction in fully-activated conductance, the net effect of the G1097W mutation ([Figure 3](#ijms-16-03071-f003){ref-type="fig"}H) is highly similar to the net effect of a 65% reduction in fully-activated conductance *per se* (G482R mutation, [Figure 3](#ijms-16-03071-f003){ref-type="fig"}G). Actually, the charge carried by *I*~f~ is reduced to ≈35% in either case ([Figure 4](#ijms-16-03071-f004){ref-type="fig"}A). Yet, no sinus node dysfunction is reported for the G1097W mutation \[[@B25-ijms-16-03071]\]. However, such a dysfunction may have become obscured by the apparent 4:1 AV block in the single index patient ([Table 1](#ijms-16-03071-t001){ref-type="table"}).

3.7. Limitations in the Reconstruction of I~f~
----------------------------------------------

The above reconstruction of *I*~f~ comes with several limitations. First, we used a single predetermined action potential waveform, with an identical cycle length and identical duration of diastolic depolarization for both wild-type and mutant *I*~f~ reconstructions. Furthermore, this single waveform was used to reconstruct *I*~f~ under control conditions, as well as upon adrenergic stimulation. We did so because recordings of human SAN action potentials upon adrenergic stimulation or with mutant *I*~f~ channels are nonexistent. In a preliminary study \[[@B42-ijms-16-03071]\], we varied the cycle length of human SAN action potential waveforms between 500 and 1500 m by manipulating the rate of diastolic depolarization and used these manipulated action potential waveforms in action potential clamp experiments on undifferentiated human cardiac myocyte progenitor cells. We found that the amplitude of HCN4 current expressed in these cells increased with increasing cycle length. Thus, the longer cycle lengths in bradycardic patients may partially counteract the *I*~f~ reduction due to mutations in *HCN4*, while shorter cycle lengths due to adrenergic stimulation may partially counteract an increase in *I*~f~. Furthermore, a prolongation of diastolic depolarization will also be counteracted by a continuing activation of *I*~Ca,L~ and deactivation of *I*~Kr~ ([Figure 2](#ijms-16-03071-f002){ref-type="fig"}D). Overall, the effects of mutations in *HCN4* and adrenergic stimulation are likely exaggerated by the use of a single fixed action potential waveform.

Second, our mathematical model of human SAN *I*~f~ \[[@B38-ijms-16-03071],[@B39-ijms-16-03071]\] is inevitably based on a highly limited amount of experimental data. These data were obtained from a small number of SAN pacemaker cells that were isolated from a single patient with inappropriate tachycardias originating from the SAN region \[[@B37-ijms-16-03071]\]. As such, there may have been abnormalities in the electrophysiology of these cells. Although the sudden onset and termination suggested that the tachycardias were based on reentrant excitation, it cannot be excluded that these tachycardias have resulted in *I*~f~ remodeling of the SAN pacemaker cells \[[@B4-ijms-16-03071]\].

Third, the *in vitro* data on the effects of mutations in *HCN4* are often incomplete. For example, data on the *I*~f~ reversal potential are mostly not provided. The same holds for data on the activation or deactivation rate and the effects of adrenergic stimulation (*cf*. [Table 2](#ijms-16-03071-t002){ref-type="table"}). In such a case, one can only assume that these are not affected by the mutation of interest.

Despite these limitations, we preferred to study *I*~f~ in simulated action potential clamp experiments, thus ensuring that the action potential followed the course of that of a human SAN pacemaker cell. An alternative would be to incorporate the human *I*~f~ equations into one of the available comprehensive mathematical models of a SAN cell, which are mostly rabbit SAN cells, but one should realize that the thus obtained data on the effects of *I*~f~ on cycle length are largely dependent on the "model environment" \[[@B43-ijms-16-03071]\].

4. Some Concluding Remarks
==========================

Since the publication of our previous review \[[@B30-ijms-16-03071]\], a large number of novel *HCN4* mutations and variants have been found. The new findings have extended our view. In particular, it has become clear that *HCN4* mutations are accompanied by more cardiac abnormalities than just sinus bradycardia and AF. Newly-found abnormalities include ventricular non-compaction \[[@B27-ijms-16-03071],[@B28-ijms-16-03071]\], prolapse of the mitral valve \[[@B27-ijms-16-03071],[@B28-ijms-16-03071]\] and AV block \[[@B25-ijms-16-03071]\]. Yet, the general picture of *HCN4* mutations as heterozygous, dominant-negative or dominant-negative-like, loss-of-function mutations remains.

Although our insights are far from complete, there are experimental data that not only relate functional loss of HCN4 to sinus bradycardia, but also to AF and AV block. For example, tachycardia-induced remodeling of ion channel expression may lead to down-regulation of *I*~f~ in dogs \[[@B44-ijms-16-03071]\]. On the other hand, chronic AF causes an up-regulation of *I*~f~ in humans \[[@B45-ijms-16-03071]\]. Furthermore, functional loss of HCN4, which is abundantly expressed in the human AV node \[[@B46-ijms-16-03071]\], has been related to AV block in an inducible cardiac-specific HCN4 knockout mouse model \[[@B47-ijms-16-03071]\].

The ventricular non-compaction and mitral valve prolapse point to a role of *HCN4* in the development of the myocardium and a role for dysfunctional HCN4 in structural abnormalities. Indeed, HCN4 is highly expressed throughout the human ventricle at early embryonic stages \[[@B48-ijms-16-03071]\]. However, it is as yet unsolved through which mechanism(s) mutations in *HCN4* lead to LVNC, which is a genetically heterogeneous disorder \[[@B49-ijms-16-03071]\] and may also involve the right ventricle \[[@B27-ijms-16-03071],[@B28-ijms-16-03071]\].

The structural determinants of HCN channel function are complex, and numerous key questions about HCN channel function are still unanswered (for detailed reviews, see Biel *et al.* \[[@B50-ijms-16-03071]\] and He *et al.* \[[@B8-ijms-16-03071]\]). The increasing number of mutations in *HCN4* identified in patients indicates that the pore-forming loop is a hotspot for mutations with severe functional effects, mostly negative shifts in activation and reduced channel expression. The exact molecular mechanisms of the functional defects are as yet unsolved, but the highly conserved GYG motif at Positions 480--482 of the HCN4 protein appears a major determinant of proper channel function. As expected, HCN4 mutations resulting in a lacking or truncated cNBD, *i.e.*, 573X and 695X, respectively, lack cAMP sensitivity \[[@B2-ijms-16-03071],[@B22-ijms-16-03071]\]. Accordingly, the contributions of the 573X and 695X mutant *I*~f~ were not increased upon adrenergic stimulation ([Figure 4](#ijms-16-03071-f004){ref-type="fig"}B).

Mutations or variants in the *N*-terminus or in the distal end of the *C*-terminus seem to have less severe functional effects. This holds in particular for the ten variants identified by Macri *et al.* \[[@B26-ijms-16-03071]\]. Nine did not affect the HCN4 channel characteristics as assessed in patch-clamp experiments ([Table 2](#ijms-16-03071-t002){ref-type="table"}) and, thus, appeared benign. The kinetic properties were also not affected by the tenth variant, *i.e.*, P257S, but a trafficking defect gave rise to a reduced expression of HCN4 at the membrane. Interestingly, the residue at Position 257 is located in the caveolin-binding domain, and a trafficking defect is in line with the effects that were previously reported for artificially generated mutations in that domain \[[@B51-ijms-16-03071]\]. Thus, the P257S variant does not have a dominant-negative effect on channel function, and its dysrhythmic mechanism is limited to haploinsufficiency. Of note, the HCN4 current was not reduced in patch-clamp experiments on heteromerically expressed P257S channels, which may point to limitations in the use of the CHO cell expression system.

With an increasing amount of data, inconsistencies remain. These include previously identified inconsistencies between clinical and experimental data \[[@B30-ijms-16-03071]\], as well as novel inconsistencies that arise from recent data. Inconsistencies between clinical and experimental data may arise from a relatively low expression or even a complete lack of HCN4 or *I*~f~ channel modulatory elements in the expression systems that are commonly used to assess mutation effects. These elements include MiRP1, PIP~2~, caveolin-3 and SAP-97 \[[@B52-ijms-16-03071],[@B53-ijms-16-03071],[@B54-ijms-16-03071],[@B55-ijms-16-03071],[@B56-ijms-16-03071]\]. Inconsistencies may also arise because experimental data are often incomplete (*cf*. [Table 2](#ijms-16-03071-t002){ref-type="table"}). In future studies involving HCN4 mutations, it may be important to follow a standardized approach, always including data on trafficking, cAMP sensitivity and kinetic properties, using appropriate experimental protocols. Apparent inconsistencies may also arise, because clinical data are, in most cases, limited to a small number of patients or even a single index patient (*cf*. [Table 1](#ijms-16-03071-t001){ref-type="table"}). Furthermore, HCN4, although abundant, is not the sole member of the HCN1--HCN4 family in the human SAN \[[@B11-ijms-16-03071]\]. It is therefore conceivable that a considerable amount of HCN tetramers is not fully built from HCN4 subunits, which may not only be important for the behavior of the wild-type current \[[@B57-ijms-16-03071]\], but also for the mutant current.

Inconsistencies arising from recent experimental data are perhaps most striking in patch-clamp data on the G482R mutation in *HCN4* obtained by Milano *et al.* \[[@B27-ijms-16-03071]\] and Schweizer *et al.* \[[@B28-ijms-16-03071]\], who studied heteromerically expressed G482R channels in CHO and HEK-293 cells, respectively. While Milano *et al.* \[[@B27-ijms-16-03071]\] found a strong hyperpolarizing shift in voltage dependence, Schweizer *et al.* \[[@B28-ijms-16-03071]\] found a strong reduction in fully-activated current without such a shift. As emphasized by DiFrancesco \[[@B7-ijms-16-03071]\], differences in protocols to measure activation curves can provide a likely explanation for differences in experimental findings from patch clamp experiments. Furthermore, differences in expression systems, recording temperatures, bath and pipette solutions and patch clamp techniques (whole-cell *vs.* perforated patch) can also contribute to the observed differences. Although an explanation for the differences in patch-clamp data between the Milano *et al.* \[[@B27-ijms-16-03071]\] and Schweizer *et al.* \[[@B28-ijms-16-03071]\] studies remains speculative, the essential difference in observed HCN4 current properties translates into marked differences in the reconstructed *I*~f~ traces ([Figure 3](#ijms-16-03071-f003){ref-type="fig"}F,G), as well as the charge carried by *I*~f~ ([Figure 4](#ijms-16-03071-f004){ref-type="fig"}).

In conclusion, the ongoing identification of *HCN4* mutations in relation to cardiac abnormalities has not only provided us with valuable information, but also with intriguing new questions regarding the role of *HCN4* and *I*~f~ in the human heart.
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